Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2022
|
Margaret G Mcglynn Director |
SELL
Open market or private sale
|
Direct |
5,000
-44.34%
|
$1,400,000
$280.84 P/Share
|
|
Apr 08
2022
|
Margaret G Mcglynn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.05%
|
$635,000
$127.54 P/Share
|
|
Apr 08
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
1,907
-26.87%
|
$533,960
$280.2 P/Share
|
|
Apr 08
2022
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,907
+21.18%
|
$238,375
$125.71 P/Share
|
|
Apr 08
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.44%
|
$556,000
$278.41 P/Share
|
|
Apr 08
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 07
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
561
-0.43%
|
$154,836
$276.37 P/Share
|
|
Apr 07
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-13.17%
|
$550,000
$275.04 P/Share
|
|
Apr 07
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 06
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-14.36%
|
$540,000
$270.72 P/Share
|
|
Apr 06
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 05
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-11.09%
|
$542,000
$271.84 P/Share
|
|
Apr 05
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 05
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
3,163
-6.8%
|
$869,825
$275.23 P/Share
|
|
Apr 04
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-20.42%
|
$534,000
$267.14 P/Share
|
|
Apr 04
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 04
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
562
-0.6%
|
$150,054
$267.76 P/Share
|
|
Apr 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,344
-2.78%
|
$353,472
$263.09 P/Share
|
|
Apr 01
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,582
-1.14%
|
$681,648
$264.56 P/Share
|
|
Apr 01
2022
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-3.46%
|
$36,031
$263.09 P/Share
|
|
Mar 31
2022
|
Margaret G Mcglynn Director |
SELL
Open market or private sale
|
Direct |
5,000
-41.03%
|
$1,310,000
$262.21 P/Share
|
|
Mar 31
2022
|
Margaret G Mcglynn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.05%
|
$635,000
$127.54 P/Share
|
|
Mar 17
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,122
-4.2%
|
$530,500
$250.06 P/Share
|
|
Mar 17
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,171
-3.22%
|
$792,750
$250.59 P/Share
|
|
Mar 17
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
2,833
-2.82%
|
$708,250
$250.67 P/Share
|
|
Feb 25
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,572
-4.61%
|
$1,749,132
$231.09 P/Share
|
|
Feb 25
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
325
-0.13%
|
$74,750
$230.94 P/Share
|
|
Feb 24
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,038
-12.15%
|
$1,370,626
$227.86 P/Share
|
|
Feb 24
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,246
-10.02%
|
$1,644,842
$227.86 P/Share
|
|
Feb 24
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-2.43%
|
$281,934
$227.86 P/Share
|
|
Feb 24
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,246
-5.57%
|
$1,644,842
$227.86 P/Share
|
|
Feb 24
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
12,141
-11.89%
|
$2,756,007
$227.86 P/Share
|
|
Feb 24
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,554
-9.71%
|
$352,758
$227.86 P/Share
|
|
Feb 24
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
7,368
-13.26%
|
$1,672,536
$227.86 P/Share
|
|
Feb 24
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,590
-4.88%
|
$587,930
$227.86 P/Share
|
|
Feb 24
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,189
-4.25%
|
$496,903
$227.86 P/Share
|
|
Feb 18
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,312
-1.65%
|
$996,072
$231.08 P/Share
|
|
Feb 18
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
519
-0.24%
|
$119,889
$231.36 P/Share
|
|
Feb 17
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-5.99%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,126
-5.4%
|
$957,232
$232.51 P/Share
|
|
Feb 17
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.31%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,584
-6.19%
|
$1,991,488
$232.51 P/Share
|
|
Feb 17
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
8,236
-7.47%
|
$1,910,752
$232.51 P/Share
|
|
Feb 17
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
712
-4.26%
|
$165,184
$232.51 P/Share
|
|
Feb 17
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,497
-5.92%
|
$811,304
$232.51 P/Share
|
|
Feb 17
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.37%
|
$797,848
$232.51 P/Share
|
|
Feb 17
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,114
-7.13%
|
$954,448
$232.51 P/Share
|
|
Feb 17
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,439
-6.25%
|
$797,848
$232.51 P/Share
|
|
Feb 14
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,444
-4.08%
|
$567,008
$232.02 P/Share
|
|
Feb 11
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,297
-0.94%
|
$539,795
$235.59 P/Share
|